Physician profile
Michael P Charlet
NPI 1023082856
$38,855.14
in general payments reported to CMS, 2019-2025
48 companies · $194 in 2025
The $194 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,679 · 2020: $1,283 · 2021: $27K · 2022: $869 · 2023: $1,100 · 2024: $324 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,617.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $26,299.95 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $5,054.32 | 2019-2023 | Kesimpta |
| Abbvie INC. | $982.33 | 2021-2025 | Botox, Ubrelvy, Duopa |
| Sunovion Pharmaceuticals INC. | $538.45 | 2019-2021 | |
| Allergan, INC. | $534.74 | 2019-2022 | |
| Genzyme Corporation | $494.40 | 2019-2023 | |
| Amgen INC. | $395.47 | 2019-2025 | Uplizna, Aimovig |
| Ucb, INC. | $367.98 | 2019-2025 | Briviact |
| Alexion Pharmaceuticals, INC. | $361.51 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $210.60 | 2019-2021 | |
| Grifols USA, LLC | $190.87 | 2019-2022 | |
| Pfizer INC. | $190.63 | 2023-2024 | |
| Biogen, INC. | $184.26 | 2019-2022 | |
| Eisai INC. | $180.69 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $170.11 | 2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Charlet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.